Business context and reporting period
The supplied filing is 180 Life Sciences Corp.’s Form 10-K for the fiscal year ended December 31, 2021, filed March 30, 2022. This does not match the request metadata naming FORUM MARKETS Inc. The filing describes a clinical-stage biotechnology company developing therapies for chronic pain, inflammation and fibrosis. Its programs target anti-TNF, synthetic cannabinoid analogs and alpha-7 nicotinic acetylcholine receptors.
This is an annual report, not a standalone fourth-quarter filing; the text does not provide a clear set of Q4-only financial results. Comparisons with 2020 require caution: the 2020 results include 180 Life’s historical operations and the combined company only after the November 6, 2020 business combination.
Financial performance and position
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | No revenue | No revenue |
| Operating expenses | $15.64 million | $5.65 million |
| Loss from operations | $15.64 million | $5.65 million |
| Net loss | $20.32 million | $10.88 million |
| Net loss per common share | $0.65 | $0.66 |
| Cash used in operating activities | $19.37 million | $3.87 million |
| Cash provided by financing activities | $25.41 million | Cash used: $8.73 million |
Cash was $8.22 million at year-end, versus $2.11 million a year earlier. Working capital deficit was $8.50 million, improved from $17.41 million. Total liabilities were $23.39 million, including $1.88 million of loans payable and $15.22 million of current derivative liabilities; convertible notes payable were zero at year-end. Stockholders’ equity was $39.32 million. The filing does not report a meaningful operating margin because the company had no revenue.
FY 2021 operating cash use reflected the net loss and working-capital changes; the company also identifies about $4.8 million of non-recurring business-combination expenses. Financing included $26.67 million of stock-and-warrant proceeds, partially offset by offering costs and debt repayments. The company raised approximately $10.8 million net in a February offering and $13.9 million net in an August offering.
Material changes and operating developments
- Net loss increased to $20.32 million from $10.88 million. Operating expenses rose substantially, chiefly from higher general and administrative costs, related-party research costs and stock-based compensation.
- General and administrative expense rose to $11.23 million from $3.17 million, reflecting higher legal and consulting fees, compensation, stock compensation and directors’ and officers’ insurance, among other items. Related-party R&D expense increased to $2.95 million from $0.08 million, including consulting and stock compensation tied to the Dupuytren’s program.
- Non-cash derivative-liability fair-value changes produced a $4.68 million expense in 2021. Other notable items included a $0.93 million gain on settlement of liabilities and $0.60 million of offering costs allocated to warrant liabilities.
- The Phase 2b trial for early-stage Dupuytren’s Contracture was completed. Top-line results announced December 1, 2021 reported statistically significant differences on the primary endpoint of nodule hardness and secondary endpoint of ultrasound-measured nodule size, with no related severe adverse events. Full results had been submitted for peer-reviewed publication; the filing does not provide the complete trial data.
- The company licensed Oxford HMGB1 technology for liver regeneration in November 2021. A Phase 2 frozen-shoulder study was in setup, with first-patient dosing anticipated in Q1 or Q2 2022; a Phase 2 POCD study was planned for Q2 2022. These were plans, not reported completed milestones.
Liquidity, outlook, risks and unusual items
Management reported a minimum monthly cash requirement of approximately $500,000. At March 28, 2022, cash was $6.05 million, and management expected available cash to fund planned operations through Q3 2022. The company has no committed credit facility, expects continuing losses and stated that additional financing is needed. The auditor’s report and financial-statement note identify substantial doubt about the company’s ability to continue as a going concern within one year after issuance. Management’s runway expectation does not eliminate that uncertainty.
Known contractual and other cash requirements were estimated at approximately $7.1 million for 2022 and $33.4 million for 2023–2026. The filing provides no revenue or earnings guidance. Management expects R&D and G&A costs to continue or increase and intends to advance development programs, subject to available capital, clinical progress and regulatory requirements.
- Clinical and regulatory risk: candidates remain investigational; success in a Phase 2 trial does not ensure later-stage success or approval. In March 2022, the FDA declined to grant a requested preliminary Type C meeting on Dupuytren’s until the company supplied more information about the product manufacturer.
- Financing and dilution: ongoing funding needs may lead to further equity issuance, dilution, debt on restrictive terms or reduced development activity. Outstanding warrants and options add potential dilution.
- Accounting and controls: management concluded disclosure controls were effective, but also reported ineffective internal control over financial reporting at year-end, including weaknesses in financial consolidation/reporting and review controls for stock compensation and payroll classification. The auditor did not provide an internal-control opinion. Prior KBL interim financial statements were restated.
- Litigation and contingencies: matters include disputes involving former KBL executives, Dr. Krauss and Tyche, as well as a 2022 claim against former consultants. The company is pursuing claims in some matters and states outcomes are uncertain; it recorded a $250,000 legal accrual related to the former-executive matter. Cantor litigation was settled and dismissed after a $200,000 payment.
- Other unusual items: the company settled EarlyBird claims with $275,000 cash and 225,000 shares valued at about $1.97 million; settled Alpha debt using shares and warrants; and converted related-party debt into shares. Management also reported $51.5 million of goodwill, intangible assets and in-process R&D, about 81% of total assets, with no impairment recorded at year-end.
- COVID-19 and partners: the pandemic delayed trial follow-up and may delay future trials. A non-binding supply memorandum with Celltrion had not become a definitive agreement by the filing date.
Important facts for investors to verify
- Confirm issuer identity: the provided filing is for 180 Life Sciences Corp. (ticker ATNF), not FORUM MARKETS Inc.
- Review the complete Dupuytren’s Phase 2b results when published, including endpoint definitions, effect sizes, statistical analyses, follow-up and safety findings.
- Check updated cash, monthly burn, financing availability and actual runway against the Q3 2022 estimate and going-concern warning.
- Track remediation of the reported internal-control material weaknesses and any subsequent financial-statement corrections.
- Review subsequent FDA correspondence, manufacturing plans, study starts and milestones for Dupuytren’s, frozen shoulder and POCD.
- Assess dilution from outstanding warrants, options and future financing, and monitor the status and potential financial impact of legal proceedings.